Oncology Other denied as experimental or investigational by Blue Cross Blue Shield?

For Anthem Blue Cross Blue Shield Marketplace (Individual & Commercial) members, oncology drugs administered under the medical benefit are delegated to Carelon Medical Benefits Management (formerly AIM Specialty Health) for prior authorization review. Carelon uses an evidence- and value-based approach utilizing cancer treatment pathways, provider-preferred clinical review, and enhanced reimbursement and pathway adherence reporting, covering approximately 85% of spending on cancer drugs across therapeutic and supportive drugs. Carelon Cancer Treatment Pathways are cancer treatment regimens intended to support quality cancer care and reduce unneeded variation in care and cost, developed through a rigorous process of integrating evidence-based literature with physician practice guidelines. Pathways identify a subset of regimens supported by clinical evidence and practice guidelines, selected based on clinical benefit (efficacy), safety/side effects (especially those leading to hospitalizations and impacting quality of life), strength of national guideline recommendations, and cost of regimens. Off-pathway requests are reviewed individually: the platform approves requests that align with policy and pathways, and board-certified medical oncologists and nurses consult on off-pathway requests and alert providers to enhanced reimbursement opportunities. For some health plans, requested services are reviewed in accordance with client medical policies and clinical guidelines; if a request is received that is not a Carelon Pathway regimen, it may be reviewed and authorized if determined to be medically necessary, with reference to NCCN Clinical Practice Guidelines in Oncology. Critical elements include confirming the diagnosis based on a complete evaluation including history, physical examination, relevant laboratory studies, diagnostic testing, and response to prior therapeutic intervention, with anticipated benefit outweighing potential harms. Self-administered/oral oncology drugs under the pharmacy benefit are reviewed against CarelonRx clinical criteria approved by the CarelonRx Pharmacy and Therapeutics Committee, an independent external committee of practicing physicians, pharmacists, and clinicians from leading academic medical centers with expertise in evidence-based medicine across all major clinical specialties.

- Carelon's own framework permits off-pathway approval when medically necessary: the treating oncologist determines if a Pathway regimen is the best option or whether, given the patient's unique circumstances, another regimen is a better choice, and non-Pathway requests may be authorized if determined to be medically necessary, referencing NCCN Clinical Practice Guidelines in Oncology. - Cite the specific NCCN Clinical Practice Guideline (Category 1 or 2A recommendation) supporting the requested regimen for the patient's histology, stage, and biomarker status — Carelon explicitly references NCCN as an authoritative source for medical necessity determinations. - Submit biomarker/pathology reports (e.g., NGS, IHC, FISH) confirming the targetable alteration required by the FDA label or NCCN guideline; Carelon requires confirmation of the diagnosis based on complete evaluation including review of relevant laboratory studies and diagnostic testing. - For step-therapy denials, document contraindication, intolerance, or prior failure of preferred agents; step therapy requires that the member has tried an alternative therapy first, or that the prescriber has clinically documented why the member cannot take the alternative therapy. - Demonstrate that benefit outweighs harm and delay would worsen outcomes: the anticipated benefit of the recommended intervention is likely to outweigh any potential harms, including from delay or decreased access to treatment. - Invoke clinician authority and individualization: medical necessity decisions may change as new information is provided or based on unique aspects of the patient's condition, and the treating clinician has final authority and responsibility for treatment decisions and for justifying medical necessity. - For Marketplace ACA plans, cite the ACA's essential health benefit protections and the plan's obligation to follow recognized compendia (NCCN Drugs & Biologics Compendium, AHFS, Micromedex DrugDex) for off-label oncology indications, which Carelon's pathway framework already incorporates via NCCN alignment.

## Why BCBS May Deny an Oncology Drug as "Experimental" and How to Appeal

Blue Cross Blue Shield plans may classify an oncology medication as "experimental" or "investigational" when their internal review determines that the evidence base does not yet meet their threshold for coverage — even if the drug has FDA approval, compendium listing, or is supported by recognized oncology guidelines. This type of denial is especially common for drugs used in off-label oncology indications, recently approved agents, or treatments used in combinations not yet widely reviewed by the plan.

### Why This Denial Is Appealable

The "experimental" classification is one of the most frequently overturned denial types in oncology appeals. Federal and most state external review laws specifically require that independent reviewers apply recognized clinical guidelines — such as those from NCCN or other major oncology guideline organizations — when assessing whether a treatment is standard of care. If the prescribed treatment is listed in a recognized oncology compendium or guideline for your specific cancer type and clinical situation, that is direct evidence against the experimental classification.

### Federal Appeal Framework

• Internal appeal: File within the timeframe on your denial notice. Under ERISA §503, you are entitled to a full-and-fair review that considers all evidence you submit, including peer-reviewed literature and guideline references your oncologist provides.
• External review (ACA §2719): You have the right to request independent external review after exhausting internal appeals, typically within four months of the final internal denial. Experimental/investigational denials are explicitly covered under ACA external review requirements.
• Expedited review: Strongly consider requesting expedited review if treatment delay would harm your health. Expedited external review typically resolves within 72 hours.

### Documentation to Gather

1. Oncologist medical-necessity letter: A detailed letter explaining that the treatment is not experimental — citing the applicable guideline organization and compendium category relevant to your diagnosis and stage, without using version-specific numbers. 2. Diagnosis and biomarker records: Pathology, genomic testing, and staging documentation that establishes the precise clinical indication for which the drug is prescribed. 3. FDA approval status: If the drug is FDA-approved for any oncology indication, note that approval. Even off-label use in oncology has recognized status under most state compendium laws. 4. Compendium listing: Your oncologist should confirm whether the use is listed in a recognized oncology drug compendium (e.g., NCCN Drugs and Biologics Compendium). 5. BCBS experimental/investigational policy: Request the written policy and criteria the plan applied so you can address each point directly.

### Criteria-Mapping Approach

| Plan's Experimental Basis | Your Appeal Evidence | |---|---| | Insufficient evidence for the indication | [Guideline organization and compendium listing, oncologist letter] | | Not standard of care | [Oncologist letter citing recognized guidelines] | | FDA status questioned | [FDA approval documentation or compendium listing] |

Oncology experimental denials are a priority area for external review — independent reviewers in this space are required to apply current clinical guidelines, which frequently results in reversals when the drug is guideline-supported.